Isoform Nell-1 peptide
View Patent ↗This application generally relates to an isoform Nell-1 peptide, compositions thereof, and methods of using the same.
1. A composition, comprising an isoform Nell-I peptide (ISN-1) consisting of the amino acid sequence according to SEQ ID NO: 1,
wherein the ISN-1 is
PEGylated,
impregnated in a synthetic matrix or synthetic bone graft material, or
a component of a prosthetic device.
2. The composition of claim 1 , further comprising a pharmaceutically acceptable carrier.
3. The composition of claim 1 , further comprising LNell-1 protein.
4. The composition of claim 2 , wherein the pharmaceutically acceptable carrier is suitable for a mode of delivery selected from the group consisting of oral administration, topical administration, in situ implant, intravenous administration, parenteral administration, local administration, intra-arterial injection, injection into a fracture site, and delivery in a biodegradable matrix.
5. The composition of claim 1 , which is formulated into a formulation suitable for a mode of delivery selected from percutaneous injection through intact skin to a site, direct injection through a surgically opened site or a trauma site, surgical implantation, extravascular delivery, extravascular injection, extravascular catheter based injection, intravascular delivery, intravascular injection, intravascular catheter based injections, intravenous delivery, intravenous injection, intravenous catheter based injections, intraarterial delivery, intraarterial injection, intraarterial catheter based injections, intrathecal delivery, intrathecal injection, intrathecal catheter based injections, intraosseous delivery, intraosseous injection, catheter based injections, intracartilaginous delivery, intracartilaginous injection, intracartilaginous catheter based injections, intravesical delivery, intravesical injection, intravesical catheter based injection, delivery via a mechanical pump with a percutaneous or implantable catheter, catheter based delivery to an area or organ in the body, or delivery via expanded dispersion through a device that increases tissue penetration or wider tissue distribution.
6. The composition of claim 1 , wherein the composition is a synthetic bone graft comprising a biocompatible matrix and the ISN-1.
7. The composition of claim 6 , wherein the ISN-1 is produced by a cell within the matrix expressing the ISN-1 which is exogenous.
8. The composition of claim 6 , wherein the biocompatible matrix is resorbable.
9. The composition of claim 6 , wherein the biocompatible matrix comprises a biodegradable polymer or a biostable polymer.
10. The composition of claim 6 , wherein the biocompatible matrix comprises a cell adhesion molecule.
11. A method of forming a composition according to claim 1 , comprising: providing the ISN-1, and forming the composition comprising the ISN 1.
12. The composition of claim 1 , wherein the synthetic matrix comprises bioglass or bioceramics.
13. The composition of claim 1 , wherein the pharmaceutically acceptable carrier comprises a polymer.
14. The composition of claim 2 , wherein the pharmaceutically acceptable carrier comprises a sustained release vehicle.